KR20200090818A - Mpges-1 억제제로서의 신규 화합물 - Google Patents

Mpges-1 억제제로서의 신규 화합물 Download PDF

Info

Publication number
KR20200090818A
KR20200090818A KR1020207017202A KR20207017202A KR20200090818A KR 20200090818 A KR20200090818 A KR 20200090818A KR 1020207017202 A KR1020207017202 A KR 1020207017202A KR 20207017202 A KR20207017202 A KR 20207017202A KR 20200090818 A KR20200090818 A KR 20200090818A
Authority
KR
South Korea
Prior art keywords
pain
compound
linker
disease
mpges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207017202A
Other languages
English (en)
Korean (ko)
Inventor
요하네스 알베르투스 마리아 스메이틴크
줄리엔 데이비드 비야스
Original Assignee
콘드리온 아이피 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘드리온 아이피 비.브이. filed Critical 콘드리온 아이피 비.브이.
Priority to KR1020257022058A priority Critical patent/KR20250109241A/ko
Publication of KR20200090818A publication Critical patent/KR20200090818A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207017202A 2017-11-22 2018-11-22 Mpges-1 억제제로서의 신규 화합물 Ceased KR20200090818A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257022058A KR20250109241A (ko) 2017-11-22 2018-11-22 Mpges-1 억제제로서의 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17203033.0 2017-11-22
EP17203033 2017-11-22
PCT/EP2018/082146 WO2019101826A1 (en) 2017-11-22 2018-11-22 Compounds as mpges-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257022058A Division KR20250109241A (ko) 2017-11-22 2018-11-22 Mpges-1 억제제로서의 화합물

Publications (1)

Publication Number Publication Date
KR20200090818A true KR20200090818A (ko) 2020-07-29

Family

ID=60450482

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207017202A Ceased KR20200090818A (ko) 2017-11-22 2018-11-22 Mpges-1 억제제로서의 신규 화합물
KR1020257022058A Pending KR20250109241A (ko) 2017-11-22 2018-11-22 Mpges-1 억제제로서의 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257022058A Pending KR20250109241A (ko) 2017-11-22 2018-11-22 Mpges-1 억제제로서의 화합물

Country Status (16)

Country Link
US (1) US11672787B2 (https=)
EP (1) EP3713564B1 (https=)
JP (2) JP7754623B2 (https=)
KR (2) KR20200090818A (https=)
CN (1) CN111417393A (https=)
AU (1) AU2018371153B2 (https=)
BR (1) BR112020010089A2 (https=)
CA (1) CA3079483A1 (https=)
ES (1) ES2963906T3 (https=)
IL (1) IL274821A (https=)
MX (1) MX2020005238A (https=)
MY (1) MY207603A (https=)
PL (1) PL3713564T3 (https=)
SG (1) SG11202003743SA (https=)
WO (1) WO2019101826A1 (https=)
ZA (1) ZA202002103B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2025730B1 (en) * 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
WO2025242849A1 (en) * 2024-05-24 2025-11-27 Khondrion Ip B.V. Chromanyl derivatives for use in the treatment of bone disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02250831A (ja) 1989-03-23 1990-10-08 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤
JP5086809B2 (ja) 2004-12-17 2012-11-28 メルク カナダ インコーポレイテッド ｍＰＧＥＳ−１阻害剤としての２−（フェニルまたはヘテロ環式）−１Ｈ−フェナントロ［９，１０−ｄ］イミダゾール
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
DE102006053475A1 (de) 2006-11-14 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
DE102006058450A1 (de) 2006-12-12 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
EA038941B1 (ru) * 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2009130242A1 (en) 2008-04-23 2009-10-29 Novasaid Ab Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
DE102008027331A1 (de) 2008-06-07 2009-12-10 Friedrich-Alexander-Universität Erlangen-Nürnberg Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en) 2011-11-16 2013-05-23 Glenmark Pharmaceuticals S.A. Phtalazinone derivatives as mpegs -1 inhibitors
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
WO2013153535A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
HRP20170532T4 (hr) * 2012-07-12 2019-12-27 Khondrion Ip B.V. Derivati kromanila za liječenje mitohondrijske bolesti
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
US10081629B2 (en) 2014-04-14 2018-09-25 Jiangsu Hengrui Medicine Co., Ltd. Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
MX388654B (es) 2015-05-22 2025-03-20 Sulfateq Bv Derivados de cromano y uso de los mismos en el tratamiento de daño en un órgano diabético, tal como un riñón.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
KR102782169B1 (ko) * 2017-11-22 2025-03-17 콘드리온 아이피 비.브이. 우울증 및 편두통 치료용 신규 화합물

Also Published As

Publication number Publication date
EP3713564B1 (en) 2023-11-15
BR112020010089A2 (pt) 2020-11-03
WO2019101826A1 (en) 2019-05-31
ZA202002103B (en) 2023-12-20
JP2024009799A (ja) 2024-01-23
MY207603A (en) 2025-03-06
EP3713564A1 (en) 2020-09-30
AU2018371153A1 (en) 2020-06-04
JP7754623B2 (ja) 2025-10-15
EP3713564C0 (en) 2023-11-15
CN111417393A (zh) 2020-07-14
SG11202003743SA (en) 2020-06-29
CA3079483A1 (en) 2019-05-31
US11672787B2 (en) 2023-06-13
IL274821A (en) 2020-07-30
AU2018371153B2 (en) 2023-07-13
JP2021504307A (ja) 2021-02-15
KR20250109241A (ko) 2025-07-16
US20200345706A1 (en) 2020-11-05
MX2020005238A (es) 2020-08-24
PL3713564T3 (pl) 2024-04-08
RU2020120235A (ru) 2021-12-22
ES2963906T3 (es) 2024-04-03

Similar Documents

Publication Publication Date Title
JP2024009799A (ja) ｍＰＧＥＳ－１阻害剤としての化合物
US20240041831A1 (en) 20-hete receptor (gpr75) antagonists and methods of use
WO2014059306A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
CZ292391B6 (cs) Derivát benzamidu substituovaný heterocyklickými skupinami a jeho použití
KR102381684B1 (ko) 피부암 치료
JP2017505299A5 (https=)
US11766423B2 (en) 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
US20240368065A1 (en) Citraconic acid and derivatives thereof for use as a medicament
TW201000482A (en) Novel pyrroloindole derivatives which inhibit HSP90, compositions containing them and use thereof
US12371401B2 (en) Dithienyl disulfiram derivatives as selective ALDH1A1 inhibitors
CN112778273B (zh) 环酮并吡啶酮类化合物及其制备方法和用途
WO2016167622A2 (ko) 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물
KR20200090816A (ko) 우울증 및 편두통 치료용 신규 화합물
RU2793330C2 (ru) НОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
HK40037579A (en) Compounds as mpges-1 inhibitors
HK40037579B (en) Compounds as mpges-1 inhibitors
US20100267827A1 (en) Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
AU2005257982A1 (en) Carbazole formulations for the treatment of psoriasis and angiogenesis
US20150374707A1 (en) Methods and Compounds for the Inhibition of Cellular Proliferation
CN111247148B (zh) Wnt通路调节剂
JP7486202B2 (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
JP2022530244A (ja) Ｇｒｋ２タンパク質インヒビター化合物および同化合物を含む医薬組成物
CA3027223C (en) Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2018079855A1 (ja) がん細胞にプログラム細胞死を誘導するための医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240514

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241204

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250401

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250401

X601 Decision of rejection after re-examination